Symbiotec Pharmalab IPO opens today: Should you apply? Check price band, GMP, reviews & key details

Symbiotec Pharmalab, whose IPO kicks-off for subscription on Monday, August 24, has managed to garner mostly positive reviews from analysts. Several brokerage firms have suggested subscribing to the issue for the long term, citing decent chances of listing gains as well. Unofficial market is also seconding their view.

Its ‘farm/microbe-to-pharmacy’ model, R&D capabilities and investments in new capacities further strengthen its long-term growth potential and support a premium positioning within the pharmaceutical manufacturing space, said Anand Rathi Shares & Stock Brokers. "We believe that the IPO is fully priced and recommend a 'subscribe for long term' rating to the IPO," it added.

Symbiotec has market leadership in steroidal APIs, strong customer relationships, backward integration and potential from emerging businesses. We believe the valuation offers an attractive entry point relative to its growth and diversification prospects, said BP Equities, which has a 'subscribe' rating on the issue.

According to Mahesh Ojha of KC Securities, Symbiotec is well positioned to benefit from the growing API, specialty pharma and nutraceutical markets. At 58.36 times post-IPO FY26 P/E, the valuation appears relatively attractive versus listed peers, and he recommended investors to 'subscribe' the issue for a long term basis.

According to Swastika Investmart, complex synthesis and stringent regulatory requirements create high entry barriers in this industry. The brokerage believes that the issue is suitable for long-term investors seeking exposure to specialized, high-barrier steroidal and hormone APIs.

With low customer churn in base businesses due to manufacturing and regulatory complexity and significant expansion across niche adjacencies with vertically integrated manufacturing platform, the company offers interesting prospects, said ICICIDirect Research. We believe Symbiotec has a long runway of growth and therefore assign a 'subscribe' rating to the issue," it said.

Symbiotec Pharmalab's differentiated proposition is its vertical integration across organic chemistry, biotechnology and regulated pharmaceutical manufacturing. Investors may consider the IPO as a potential long-term investment opportunity, said Master Capital Services in its IPO note. Other brokerage firms including SMIFS and Ventura also have suggested to subscribe to it.

The Rs 1,757 crore IPO of Symbiotec Pharmalab is being sold in the range of Rs 938-988 apiece, with a lot size of 15 equity shares and its multiples thereafter. The IPO will close for subscription on Thursday, August 27, considering a bank holiday on Wednesday, August 26. The IPO includes a fresh share sale of Rs 150 crore and an offer-for-sale (OFS) of Rs 1,607 crore.

Incorporated in 2002, Indore-based Symbiotec Pharmalab is a pharmaceutical and biotechnology firm engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. It serves domestic and international markets across regulated and emerging regions.

Ahead of its IPO, Symbiotec Pharmalab raised Rs 526.2 crore from 34 anchor investors as it allocated 53,25,909 equity shares at Rs 988 apiece. Its anchor investors included names like ICICI Pru MF, HDFC MF, Ashoka Whiteoak ICAV, Motilal Oswal MF, Mirae Asset MF, Tata India MF, Prazim Trading & Investment Company, Manulife Global Fund, Tata AIA Life Insurance, TIMF Holdings & more.

Symbiotec Pharmalab's revenue increased by 15 per cent on a yearly basis to Rs 872.26 crore and profit after tax (PAT) increased 14 per cent YoY to Rs 109.90 crore for the financial year ended on March 31, 2026. The company clocked a topline and bottomline of Rs 755.98 crore and Rs 96.79 crore for the financial year 2024-25.

The company has reserved 50 per cent for the net offer for institutional bidders, while retail investors and HNI bidders will get 35 per cent and 15 per cent shares, respectively. The company currently commands a market capitalization close to Rs 6,250 crore and its grey market premium stood at Rs 410-415, suggesting an upside potential of nearly 40 per cent for investors.

JM Financial Ltd, Nomura Financial Advisory & Securities (India), Motilal Oswal Investment Advisors and Avendus Capital are the book running lead managers and MUFG Intime India is the registrar of the issue. Shares of the company shall be listed on both BSE Ltd and NSE on Tuesday, September 1.